We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| C4x Discovery Holdings Plc | C4XD | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.025 | -0.27% | 9.40 | 13:52:11 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 9.40 | 9.40 | 10.00 | 9.425 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 09/4/2024 13:02 by takeiteasy 9 April 2024 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, was informed on 8 April 2024 that Clive Dix, Executive Chairman of the Company, purchased 485,320 ordinary shares of 0.01 pence each ("Ordinary Shares") in the Company at a price of 10.3 pence per share.Following this purchase of shares, Clive Dix has a beneficial interest in 2,071,809 Ordinary Shares, representing approximately 0.82 per cent. of the Company's issued share capital. nice timing :) lols |
Posted at 22/1/2024 21:07 by bloomberg2 ETX usually the poor relation!! To C4XD .... |
Posted at 20/1/2024 08:49 by takeiteasy An evolutionary yearHunjan said that C4XD is always in discussions with potential partners as they progress their programmes along the development pathway, and partnership is something that could eventually happen with its ongoing work on IBD and other inflammatory diseases. The company is also planning to publish results from its analysis, using PatientSeek, of two phase three clinical trials for Parkinson’s with the Garvan Institute of Medical Research. The sheer broad range of the work being considered is what makes this such a fascinating business to link up with if you have an interest in the world of auto-immunity dyor and no advice intended |
Posted at 06/1/2024 06:54 by takeiteasy UPDATE: Dr Julie Simmonds at Panmure Gordon commented: “C4XD has received an $11m milestone payment from AstraZeneca. We update our estimates. The payment, in addition to the divestment of the Orexin programme in July which generated £16m, means we expect the company to end the year (July) with Net Cash of £22m, the current market capitalization. C4XD is very good value with a strong drug development engine; there are few companies which have successfully developed and out-licensed three differentiated products. We reiterate our BUY recommendation.̶hxxps://www.thebusin hxxps://www.lgbco.co |
Posted at 05/1/2024 14:41 by mirabeau DM - todayIt’s fair to say C4X Discovery had a fantastic start with the shares advancing 113 per cent over the foreshortened trading week after drug giant AstraZeneca delivered an $11million post-Christmas windfall. It came in the form of what the experts call a ‘milestone payment’ under a $402million deal with Anglo-Swedish giant, which has licensed the right to NRF2 activator, created by C4XD to tackle chronic respiratory disease. Analysts said the payment went further than adding a material sum to the AIM company’s coffers – it provided third-party validation of the technology. 'We see this as an important value inflexion which should reinvigorate sentiment in the share,' said regional broker Shore Capital. 'Moreover, this serves as a timely reminder that C4XD has licensing deals in place with some of the leading developers for its programmes.' |
Posted at 03/1/2024 11:39 by intoodeep News of C4X Discovery Holdings PLC (AIM:C4XD)’s latest payment from AstraZeneca PLC (LSE:AZN) solidifies and validates the company’s place as a skilled drug developer, analysts have said.Following the firm’s update that US$11 million had been received under a deal worth up to US$400 million with AstraZeneca for the NRF2 activator programme, Shore Cap analysts backed aim-listed C4X. “We see this as an important value inflection which should reinvigorate sentiment in the share,” the bank said in a note. “Moreover, this serves as a timely reminder that C4XD has licensing deals in place with some of the leading developers for its programmes.” The deal included an initial upfront payment of US$2 million to C4X and consisted of a series of developmental and commercial milestones. Under this, C4X’s NRF2 activator programme has been out-licensed to AstraZeneca with the goal of creating an oral therapy for inflammatory and respiratory diseases. Shore Cap added that its model for C4X suggested fair value of 52p per share, marking a prospective 480% increase on Tuesday’s closing value of 8.7p. “These agreements serve as strong validation of C4XD’s prowess in drug discovery and demonstrate its ability to distil value from assets early in the development process,” the bank said. Indeed, the market reacted positively to the news, with shares in C4X climbing 37% to 11.98p following the news on Wednesday morning. |
Posted at 03/1/2024 09:13 by luckyabbeygale I asume C4X may pay a great dividend in the future. |
Posted at 03/1/2024 08:35 by davemac3 C4XD now looks as good as it ever has |
Posted at 03/1/2024 07:35 by alanrussell £4.2 cash at year end, since received £16m and now £11m. Say cash burn £12 pa so £4m since year end. So perhaps £27m in bank now and £19m at year end 24.Special dividend? |
Posted at 13/6/2023 23:47 by alloa2003 I dont know if anyone has noticed but PatientSeek could be a game changer for C4XD, on top of the potential drug revenues further down the line. In the test they were able to tell, using a person's DNA, which Parkinsons treatment would work best for each patient. Personal medication - the Holy Grail - with potentially massive life and cost savings for the NHS, etc.We should be discussing this as well. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
